| Title |
Clinical efficacy of computed tomography-guided iodine-125 seed implantation therapy in patients with advanced spinal metastatic tumors
|
|---|---|
| Published in |
OncoTargets and therapy, December 2015
|
| DOI | 10.2147/ott.s95410 |
| Pubmed ID | |
| Authors |
Liyun Zhang, Jian Lu, Zhongmin Wang, Yingsheng Cheng, Gaojun Teng, Kemin Chen |
| Abstract |
The purpose of this study was to examine the safety and clinical efficacy of computed tomography (CT)-guided radioactive iodine-125 ((125)I) seed implantation treatment in patients with spinal metastatic tumors. We retrospectively analyzed 20 cases of spinal metastatic tumors, including nine men and eleven women aged 50-79 years (mean age: 61.1 years). We used treatment planning system (TPS) to construct three-dimensional images of the spinal metastatic tumors and to determine what number and dose rate distribution to use for the (125)I seeds. The matched peripheral dose of the (125)I seed implantation was 90-130 Gy. Twenty-four spinal metastatic tumors were treated by CT-guided radioactive (125)I seed implantation. A median of 19 (range: 4-43) (125)I seeds were implanted. Twenty cases were followed for a median of 15.3 months (range: 7-32 months). The rate of pain relief was 95%. The median control time for all of the patients was 12.5 months. The 3-, 6-, and 12-month cumulative local control rates were 100%, 95%, and 60%, respectively. The median survival time for all of the patients was 16 months. The cumulative 6- and 12-month survival rates were 100% and 78.81%, respectively. No major complications were observed. No (125)I seeds were lost or migrated to other tissues or organs. CT-guided radioactive (125)I seed implantation is a safe, effective, and minimally invasive method for the treatment of patients with spinal metastatic tumors. It is a possible alternative therapy for the treatment of spinal metastases. |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 18% |
| Student > Doctoral Student | 1 | 9% |
| Other | 1 | 9% |
| Student > Ph. D. Student | 1 | 9% |
| Researcher | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 5 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 18% |
| Nursing and Health Professions | 1 | 9% |
| Physics and Astronomy | 1 | 9% |
| Engineering | 1 | 9% |
| Unknown | 6 | 55% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 December 2015.
All research outputs
#20,299,108
of 22,836,570 outputs
Outputs from OncoTargets and therapy
#1,970
of 2,933 outputs
Outputs of similar age
#324,856
of 387,565 outputs
Outputs of similar age from OncoTargets and therapy
#68
of 91 outputs
Altmetric has tracked 22,836,570 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,933 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 387,565 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.